<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586311</url>
  </required_header>
  <id_info>
    <org_study_id>144HT15027</org_study_id>
    <nct_id>NCT02586311</nct_id>
  </id_info>
  <brief_title>CKD-330 Phase 3 Trial in Amlodipine Non-responder</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in
      Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety
      of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled
      by Amlodipine Monotherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change of sitSBP(sitting Systolic blood pressure)</measure>
    <time_frame>From baseline at week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change of sitSBP(sitting Systolic blood pressure)</measure>
    <time_frame>From baseline at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of sitDBP(sitting diastolic blood pressure)</measure>
    <time_frame>From baseline at week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Control rate</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Patient achieving sitSBP &lt; 140mmHg and sitDBP &lt; 90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Response rate</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>sitSBP reduction ≥ 20mmHg and sitDBP reduction ≥ 10mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD-330 16/5mg + Amlodipine 5mg placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-330 16/5mg placebo + Amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 16/5mg</intervention_name>
    <description>Once a day, 8 weeks</description>
    <arm_group_label>CKD-330 16/5mg + Amlodipine 5mg placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg Placebo</intervention_name>
    <description>Once a day, 8 weeks</description>
    <arm_group_label>CKD-330 16/5mg + Amlodipine 5mg placebo</arm_group_label>
    <other_name>Norvasc 5mg Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 16/5mg Placebo</intervention_name>
    <description>Once a day, 8 weeks</description>
    <arm_group_label>CKD-330 16/5mg placebo + Amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>Once a day, 8 weeks</description>
    <arm_group_label>CKD-330 16/5mg placebo + Amlodipine 5mg</arm_group_label>
    <other_name>Norvasc 5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 19 or above

          -  Essential hypertension with 140mmHg ≤ mean sitSBP &lt; 180mmHg on target arm at Visit 2

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  The difference between arms of sitSBP ≥ 20mmHg and/or sitDBP ≥ 10mmHg at Visit 1

          -  mean sitSBP ≥ 200mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 1

          -  mean sitSBP ≥ 180mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 2

          -  Known or suspected Secondary Hypertension

          -  Type I Diabetes Mellitus and Type II Diabetes Mellitus with HbA1c &gt; 9%

          -  Patients with severe congestive heart failure(NYHA class III, IV)

          -  Patient with ischemic heart disease, Ischemic cardiovascular disease, Valvular heart
             disease, arrhythmia requiring treatment within 3 months

          -  History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within
             6 months

          -  History of severe or malignant retinopathy

          -  AST/ALT ≥ UNL*3, Serum creatinine ≥ UNL*1.5, K &gt; 5.5mEq/L

          -  Patients with acute or chronic inflammatory status requiring treatment

          -  Patient who need to take antihypertensive drug besides Investigational products

          -  Patient must be treated with medications prohibited for concomitant use during the
             study period

          -  History of angioedema related to ACE inhibitor or angiotensin II receptor blockers

          -  History of disability to drug ADME, active inflammatory bowel syndrome within
             12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract

          -  History of malignant tumor within 5 years

          -  Patient who are dependent on drugs or alcohol within 6 months

          -  Hypersensitive to Candesartan/Amlodipine

          -  Women with pregnant, breast-feeding

          -  Patients treated with other investigational product within 30 days at first time
             taking the investigational product

          -  Not eligible to participate for the study at the discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Gyu Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

